Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NT-112

Cell therapy (TCR-T) · Kills target cells, directed at KRAS G12D (KRAS) · developed by AstraZeneca

Phase 1 Most advanced trial

AZN Developer

1 Registered trials

What is NT-112?

NT-112 is a T-cell receptor (TCR) engineered T-cell therapy targeting KRAS G12D presented on HLA-C*08:02. It is being studied in patients with KRAS G12D-mutant non-small cell lung cancer, colorectal cancer, pancreatic cancer, and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (TCR-T)
Targets: KRAS G12D (KRAS) (antigen), HLA-C*08:02 (binding partner it blocks)
Mechanism: Kills target cells, directed at KRAS G12D (KRAS)
Therapy area: Oncology
Developer: AstraZeneca (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06218914	Phase 1	Non-small Cell Lung Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CarcinomaEndometrial CancerKRAS G12DNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaSolid Tumor, Adult

Other drugs acting on KRAS

Sotorasib FDA approved AN9025 Phase 1 ARV-806 Phase 1/2 Calderasib Phase 3 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

More from AstraZeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

ClinicalTrials.gov NCT06218914

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind NT-112

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z